Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04445389
Recruitment Status : Recruiting
First Posted : June 24, 2020
Last Update Posted : June 26, 2020
Sponsor:
Information provided by (Responsible Party):
Genexine, Inc.

Brief Summary:
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Drug: GX-19 Drug: Saline Phase 1 Phase 2

Detailed Description:

This clinical study is phase 1/2a clinical trial to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive vaccine by intramuscularly administration in healthy volunteers.

Phase 1 of this study is designed as dose escaltion, single arm, open-labeled and a total of 40 subjects will be enrolled. Phase 2a of study is designed as randomized, double-blind, placebo controlled and a total of 150 subjects are planned to be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 190 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects
Actual Study Start Date : June 17, 2020
Estimated Primary Completion Date : March 17, 2021
Estimated Study Completion Date : June 17, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GX-19: Dose A
Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
Drug: GX-19
DNA vaccine expressing SARS-CoV-2 S-protein antigen
Other Name: DNA vaccine expressing SARS-CoV-2 S-protein antigen

Experimental: GX-19: Dose B
Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
Drug: GX-19
DNA vaccine expressing SARS-CoV-2 S-protein antigen
Other Name: DNA vaccine expressing SARS-CoV-2 S-protein antigen

Placebo Comparator: Placebo: Dose A or B
Placebo will be intramusculary administered on day 1 and day 29 via EP.
Drug: Saline
Saline




Primary Outcome Measures :
  1. Incidence of solicited adverse events [ Time Frame: Through 1 year post vaccination ]
    solicited local and systemic AEs after vaccination

  2. Incidence of unsolicited adverse events [ Time Frame: Through 1 year post vaccination ]
    unsolicited AEs after vaccination

  3. Incidence of serious adverse events [ Time Frame: Through 1 year post vaccination ]
    percentage of subjects with SAEs


Secondary Outcome Measures :
  1. Geometric mean titer (GMT) of antigen-specific binding antibody titers [ Time Frame: Through 1 year post vaccination ]
    Change from baseline in antigen-specific binding antibody titers

  2. Percentage of subjects who seroconverted after vaccination [ Time Frame: Through 1 year post vaccination ]
    Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination

  3. Geometric mean titer (GMT) of neutralizing antibody level [ Time Frame: Through 1 year post vaccination ]
    NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination

  4. Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers [ Time Frame: Through 1 year post vaccination ]
    Change from baseline in antigen-specific binding antibody titers


Other Outcome Measures:
  1. Change from baseline in antigen-specific IFN-g cellular immune response [ Time Frame: Through 1 year post vaccination ]
    Antigen-specific IFN-γ T cell immune response assessed before/after vaccination



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Each participant must meet all of the following criteria during the screening period:

  1. Able and willing to comply with all study procedures and voluntarily signs informed consent form
  2. Healthy adult male or female aged 19-55 years
  3. Those who weigh 50 kg to 90kg and have a body mass index (BMI) of 18.0 kg/m2 to 28.0 kg/m2 at screening visit.
  4. Willing to provide specimens such as blood and urine during the study, including end of study visit.

Exclusion Criteria:

Participants meeting any of the following criteria at the Screening Visit:

  1. Immunosuppresion including immunodeficiency disease or family history
  2. Any history of malignant disease within the past 5 years
  3. Scheduled to undergo any surgery or dental treatment during the study
  4. Having received immunoglobulin or blood-derived drugs or being expected to be administered within 3 months prior to administration.
  5. Having relied on antipsychotic drugs and narcotic analgesics within 6 months before administration
  6. Positive of serum test at screening
  7. Suspected of drug abuse or a history within 12 months prior to administration
  8. Active alcohol use or history of alcohol abuse
  9. Serious adverse reaction to a drug containing GX-19 or other ingredients of the same categories or to a vaccine or antibiotic, nonsteroidal anti-inflammatory disease control, etc. or an allergic history
  10. History of hypersensitivity to vaccination such as Guillain-Barre syndrome
  11. Those who have or with a history of disease corresponding to other hepatobiliary, kidneys, nervous systems (middle or peripheral), respiratory machines (e.g. asthma, pneumonia, etc., endocrine systems (uncontrolled diabetes, hyperlipidemia, etc.) and cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension), blood tumors, urinary machines, mental, musculoskeletal systems, immune system (rheumatoid arthritis, systemic arthritis, mumps, immunodeficiency disease)
  12. Having hemophilia at risk of causing serious bleeding when injected intramuscularly or receiving anticoagulants
  13. Subjects who have been contact with COVID-19 infections in the past prior to administration, have been classified as COVID-19 confirmed patients, medical patients or patients with symptoms or have been identified with SARS and MERS infection history in the past
  14. Acute fever, cough, difficulty breathing, chills, muscle aches, headache, sore throat, loss of smell, or loss of taste within 72 hours prior to administration
  15. Other vaccination history within 28 days prior to the administration or being scheduled to be inoculated during the study
  16. History of having taken immunosuppressant or Immune modifying drug within 3 months prior to administration
  17. Having participated and had clinical trial drug administration in another clinical trial or biological equivalence study within 6 months prior to the administration
  18. Pregnant or breastfeeding female, however, those are allowed to participate in the study only if they stop breastfeeding before participation (fertile female† must be negative in serum pregnancy test at screening
  19. Fertile female who do not agree to use effective contraception methods (condoms, contraceptive diaphragm, intrauterine contraceptive devices) during the study
  20. Any other clinically significant medical or psychiatric finding which is considered inappropriate by investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04445389


Contacts
Layout table for location contacts
Contact: Yoon-Jeong Choi, M.S. 82-31-628-3233 yoonjeong.choi@genexine.com

Locations
Layout table for location information
Korea, Republic of
Severance hospital Recruiting
Seoul, Korea, Republic of, 03722
Contact: Yoon-Jeong Choi, M.S.    82-31-628-3233    yoonjeong.choi@genexine.com   
Contact: Wonjin Lee, B.S.    82-31-628-3278    wonjin.lee@genexine.com   
Principal Investigator: Jun Yong Choi, MD         
Principal Investigator: Young Goo Song, MD         
Sponsors and Collaborators
Genexine, Inc.
Investigators
Layout table for investigator information
Study Director: JungWon Woo, Ph.D. Genexine, Inc.
Layout table for additonal information
Responsible Party: Genexine, Inc.
ClinicalTrials.gov Identifier: NCT04445389    
Other Study ID Numbers: GX-19-HV-001
First Posted: June 24, 2020    Key Record Dates
Last Update Posted: June 26, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs